- Home
- GRRR vs ACET Comparison
GRRR vs ACET Comparison
Compare GRRR & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRRR
- ACET
- Stock Information
- Founded
- GRRR 2001
- ACET 1947
- Country
- GRRR United Kingdom
- ACET United States
- Employees
- GRRR N/A
- ACET N/A
- Industry
- GRRR Computer Software: Prepackaged Software
- ACET Biotechnology: Pharmaceutical Preparations
- Sector
- GRRR Technology
- ACET Health Care
- Exchange
- GRRR Nasdaq
- ACET Nasdaq
- Market Cap
- GRRR 85.6M
- ACET 93.1M
- IPO Year
- GRRR N/A
- ACET N/A
- Fundamental
- Price
- GRRR $13.37
- ACET $0.91
- Analyst Decision
- GRRR Buy
- ACET Strong Buy
- Analyst Count
- GRRR 1
- ACET 4
- Target Price
- GRRR $13.00
- ACET $5.67
- AVG Volume (30 Days)
- GRRR 2.7M
- ACET 776.5K
- Earning Date
- GRRR 01-03-2025
- ACET 11-06-2024
- Dividend Yield
- GRRR N/A
- ACET N/A
- EPS Growth
- GRRR N/A
- ACET N/A
- EPS
- GRRR 2.28
- ACET N/A
- Revenue
- GRRR $78,940,347.00
- ACET N/A
- Revenue This Year
- GRRR $12.29
- ACET N/A
- Revenue Next Year
- GRRR $21.40
- ACET N/A
- P/E Ratio
- GRRR $5.87
- ACET N/A
- Revenue Growth
- GRRR 424.97
- ACET N/A
- 52 Week Low
- GRRR $2.09
- ACET $0.81
- 52 Week High
- GRRR $14.37
- ACET $3.77
- Technical
- Relative Strength Index (RSI)
- GRRR 87.34
- ACET 37.30
- Support Level
- GRRR $5.75
- ACET $0.81
- Resistance Level
- GRRR $8.24
- ACET $0.98
- Average True Range (ATR)
- GRRR 1.32
- ACET 0.08
- MACD
- GRRR 0.60
- ACET -0.00
- Stochastic Oscillator
- GRRR 88.40
- ACET 31.25
About GRRR Gorilla Technology Group Inc. Ordinary shares
Gorilla Technology Group Inc is primarily engaged in providing information, software, and data processing services. It is a provider of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology (OT) security solutions and services. Its reportable segments are video IoT and security convergence and Other segments.
About ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its lead product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its lead preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.